Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This phase I/II trial is studying the side effects and best dose of SGN-30 when given
together with ifosfamide, carboplatin, and etoposide and to see how well they work in
treating young patients with recurrent anaplastic large cell lymphoma. Drugs used in
chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop
the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as SGN-30, can block cancer growth in different ways. Some block
the ability of cancer cells to grow and spread. Others find cancer cells and help kill them
or carry cancer-killing substances to them.